In the French pharmaceutical industry, there were 6 private equity deals announced in Q2 2023, worth a total value of $109.4m, according to GlobalData’s Deals Database. The $107.2m investment by ardian holding in Mon Veto was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in France increased by 8% in Q2 2023 compared with the previous quarter’s total of $101.1m and rose by 307% as compared to Q2 2022. Related deal volume remained flat in Q2 2023 versus the previous quarter and was 100% higher than in Q2 2022.
The top-ranked financial advisors supporting these private equity deals in France in Q2 2023 were Clearwater International Ltd (France); Deloitte Conseil; Germain Maureau with 1, 1, 1 deals respectively.
The top-ranked legal advisorss supporting these private equity deals in France Q2 2023 were McDermott Will & Emery; CMS Legal Services EEIG; DLA Piper with 2, 1, 1 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.